Do Wegovy and Mounjaro Reduce Alcohol Cravings? What the Evidence Shows
Small trials suggest semaglutide can reduce heavy drinking and alcohol craving. What the evidence shows, what it doesn't, and what drinking on Wegovy or Mounjaro involves.

Do Wegovy and Mounjaro Reduce Alcohol Cravings? What the Evidence Shows
Many people taking Wegovy (semaglutide) or Mounjaro (tirzepatide) report that they want to drink less. Researchers have taken this seriously, and randomised trials of semaglutide in people with alcohol use disorder have now been published. This article covers what those trials found, what drinking alcohol while taking these medicines involves, and why neither medicine is a treatment for alcohol problems in the UK.
What the evidence supports is a modest but real reduction in heavy drinking with semaglutide in small trials. The evidence for tirzepatide is much thinner. Neither medicine is licensed to treat alcohol use disorder.
The short answer
- Small randomised trials found semaglutide reduced heavy drinking days and craving compared with placebo.
- The largest so far, published in The Lancet in 2026, involved 108 people over 26 weeks.
- There are no comparable trials for tirzepatide yet.
- Neither medicine is licensed for alcohol use disorder, and alcohol can worsen some of their side effects.
Why GLP-1 medicines might affect drinking
GLP-1 receptors are found in parts of the brain involved in reward and motivation, not only in the gut and pancreas. Animal studies suggest that activating these receptors dampens the reward response to alcohol. In people, this may show up as reduced craving or less interest in a second drink. The mechanism is still being studied, and it is not yet known how much of the effect in people comes from the brain and how much from slower digestion or nausea. Our article on what GLP-1 medications are explains the hormone itself.
What the trials found
Hendershot and colleagues, JAMA Psychiatry, 2025. This trial randomised 48 adults with alcohol use disorder who were not seeking treatment to low-dose weekly semaglutide or placebo for nine weeks. Semaglutide did not change the overall number of drinking days, but it reduced the number of drinks on days when people did drink, and reduced weekly craving. In a laboratory test at the end, people on semaglutide drank less.
Klausen and colleagues, The Lancet, 2026. This Danish trial randomised 108 adults with alcohol use disorder and obesity, all receiving standard cognitive behavioural therapy, to semaglutide 2.4 mg or placebo for 26 weeks. The proportion of heavy drinking days fell by 41.1 percentage points with semaglutide and 26.4 points with placebo. Total alcohol intake and craving also fell more on semaglutide.
Both trials were small and short, and one was at a single centre. Commentators noted that drinking after treatment ended was not followed up, so it is not known whether the effect persists.
Observational studies of large health records have linked GLP-1 medicines with fewer alcohol-related hospital admissions. These studies show association rather than cause, because people prescribed these medicines may differ in other ways.
Drinking alcohol while taking Wegovy or Mounjaro
Neither medicine carries a ban on alcohol, but several effects overlap:
- Gastrointestinal side effects. Alcohol can worsen nausea, vomiting and reflux, which are already common, particularly after a dose increase.
- Dehydration. Vomiting and diarrhoea, combined with alcohol, increase the risk of dehydration and kidney strain.
- Low blood sugar. People who also take insulin or a sulfonylurea for diabetes are at higher risk of hypoglycaemia, and alcohol adds to that risk.
- Pancreatitis. Heavy drinking is a recognised cause of pancreatitis, a rare but serious side effect also listed for these medicines.
UK guidance for all adults is to drink no more than 14 units a week, spread over several days. Seek urgent medical help for severe or persistent abdominal pain, sometimes spreading to the back, persistent vomiting, or signs of dehydration such as dizziness and passing very little urine. Suspected side effects can be reported through the MHRA Yellow Card scheme.
What this means in practice
A reduced desire to drink may be a welcome effect for some people, but it is not a reason to start either medicine. Wegovy and Mounjaro are licensed for weight management in people who meet specific criteria, which are explained in our guide to who is suitable for weight loss medication. Anyone worried about their drinking can speak to their GP, who can refer to local alcohol services and discuss treatments licensed for alcohol dependence.
The bottom line
The evidence that semaglutide can reduce heavy drinking is promising and comes from randomised trials, but those trials are small, short and limited to semaglutide. It is not yet known whether the effect lasts, applies to tirzepatide, or works outside a research setting. For weight management or alcohol concerns, a GP or regulated UK prescriber is the right first conversation.
Sources and further reading
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405.
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687–1698.
- Wegovy (semaglutide) SmPC (EMC)
- Mounjaro (tirzepatide) SmPC (EMC)
- NHS: Alcohol units
Related reading from the Health Hub
- Wegovy side effects: what to expect
- Mounjaro side effects and tolerability
- Stress and wellbeing on Wegovy or Mounjaro
Always speak to your GP or a regulated UK prescriber before starting, stopping or changing any medication. This article is for general information only and does not replace individual medical advice.
Get weekly weight loss tips
Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.
Subscribe free